Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CRISPR Therapeutics Q1 EPS $(1.43) Misses $(1.42) Estimate, Sales $504.00K Miss $28.11M Estimate

Author: Benzinga Newsdesk | May 08, 2024 05:01pm
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.42) by 0.7 percent. This is a 113.43 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $504.00 thousand which missed the analyst consensus estimate of $28.11 million by 98.21 percent. This is a 99.50 percent decrease over sales of $100.00 million the same period last year.

Posted In: CRSP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist